Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial

Cancer Prevention Research

Volumn 1, Issue 1, 2008, Pages 32-38

  Meyskens Jr , Frank L ^a   McLaren, Christine E ^a   Pelot, Daniel ^a   Fujikawa Brooks, Sharon ^a   Carpenter, Philip M ^a   Hawk, Ernest ^i,j   Kelloff, Gary ⁱ   Lawson, Michael J ^g   Kidao, Jayashri ^c   McCracken, John ^d   Albers, C Gregory ^a   Ahnen, Dennis J ^f   Turgeon, D Kim ^e   Goldschmid, Steven ^b   Lance, Peter ^b   Hagedorn, Curt H ^h   Gillen, Daniel L ^a   Gerner, Eugene W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF KANSAS   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EFLORNITHINE; PLACEBO; SULINDAC;

ADENOMA; ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOMA; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONOSCOPY; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; EFLORNITHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SULINDAC; TREATMENT OUTCOME;

EID: 55549132996     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0042     Document Type: Article

References (32)

1. Minino AM, Heron MP, Murphy SL, Kochanek KD. Centers for Disease Control and Prevention National Center for Health Statistics National Vital Statistics S. Deaths: final data for 2004. Natl Vital Stat Rep 2007;55:1-119.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Winawer SJ, Zauber AG, Ho MN, et al. The National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-81.
4. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 2004;127:1661-9[see comment].
5. Gross CP, Andersen MS, Krumholz HM, McAvay GJ, Proctor D, Tinetti ME. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA 2006;296:2815-22.
6. Greenwald P. Lifestyle and medical approaches to cancer prevention. Recent Results Cancer Res 2005;166:1-15.
7. Alberts DS, Martinez ME, Roe DJ, et al. Phoenix Colon Cancer Prevention Physicians' Network. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000;342:1156-62.
8. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
9. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-7.
10. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
11. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82.
12. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
13. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
14. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1070-80.
15. Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 2006;3:523.
16. Sporn MB. Combination chemoprevention of cancer. Nature 1980;287:107-8.
17. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
18. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77:1309-13.
19. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945-51.
20. Gerner EW, Meyskens FL, Jr., Goldschmid S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 2007;33:189-95Epub 2007 Mar 30.
21. Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 2000; 9:1155-62.
22. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35: 549-56.
23. Kittelson JM, Emerson SS. A unifying family of group sequential test designs. Biometrics 1999; 55:874-82.
24. Burington BE, Emerson SS. Flexible implementations of group sequential stopping rules using constrained boundaries. Biometrics 2003; 59:770-7.
25. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials 1999. New York (NY): Chapman and Hall, CRC Press.
26. Meyskens FL, Jr., Emerson SS, Pelot D, et al. Dose de-escalation chemoprevention trial of α-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994;86:1122-30.
27. Meyskens FL, Jr., Gerner E, Emerson S, et al. Effect of α-difluoromethylornithine on rectal mucosal levels for polyamines in a randomized, doubleblinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8.
28. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
29. McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998;105:3-9S.
30. McCarthy DM. Comparative toxicity of nonsteroidal anti-inflammatory drugs. Am J Med 1999;107: 37-46S; discussion 46-7S [review].
31. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
32. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.